503 related articles for article (PubMed ID: 27976373)
21. Heme oxygenase-1 inhibition mediates Gas6 to enhance bortezomib-sensitivity in multiple myeloma via ERK/STAT3 axis.
Zhang Z; Wang W; Ma D; Xiong J; Kuang X; Zhang S; Fang Q; Wang J
Aging (Albany NY); 2020 Apr; 12(8):6611-6629. PubMed ID: 32298237
[TBL] [Abstract][Full Text] [Related]
22. Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1-Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow.
Zhang C; Xu X; Trotter TN; Gowda PS; Lu Y; Suto MJ; Javed A; Murphy-Ullrich JE; Li J; Yang Y
Mol Cancer Ther; 2022 Feb; 21(2):347-358. PubMed ID: 34907087
[TBL] [Abstract][Full Text] [Related]
23. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
Maiso P; Ocio EM; Garayoa M; Montero JC; Hofmann F; García-Echeverría C; Zimmermann J; Pandiella A; San Miguel JF
Br J Haematol; 2008 May; 141(4):470-82. PubMed ID: 18341634
[TBL] [Abstract][Full Text] [Related]
24. An inhibitor of cholesterol absorption displays anti-myeloma activity by targeting the JAK2-STAT3 signaling pathway.
Xu X; Han K; Zhu J; Mao H; Lin X; Zhang Z; Cao B; Zeng Y; Mao X
Oncotarget; 2016 Nov; 7(46):75539-75550. PubMed ID: 27705908
[TBL] [Abstract][Full Text] [Related]
25. Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib.
Camiolo G; Barbato A; Giallongo C; Vicario N; Romano A; Parrinello NL; Parenti R; Sandoval JC; García-Moreno D; Lazzarino G; Avola R; Palumbo GA; Mulero V; Li Volti G; Tibullo D; Di Raimondo F
Redox Biol; 2020 Sep; 36():101611. PubMed ID: 32863212
[TBL] [Abstract][Full Text] [Related]
26. Collaboration of cancer-associated fibroblasts and tumour-associated macrophages for neuroblastoma development.
Hashimoto O; Yoshida M; Koma Y; Yanai T; Hasegawa D; Kosaka Y; Nishimura N; Yokozaki H
J Pathol; 2016 Oct; 240(2):211-23. PubMed ID: 27425378
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
28. Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
De Smedt E; Maes K; Verhulst S; Lui H; Kassambara A; Maes A; Robert N; Heirman C; Cakana A; Hose D; Breckpot K; van Grunsven LA; De Veirman K; Menu E; Vanderkerken K; Moreaux J; De Bruyne E
Cancer Res; 2018 Mar; 78(5):1155-1168. PubMed ID: 29259009
[TBL] [Abstract][Full Text] [Related]
29. Using macrophage activation to augment immunotherapy of established tumours.
Fridlender ZG; Jassar A; Mishalian I; Wang LC; Kapoor V; Cheng G; Sun J; Singhal S; Levy L; Albelda SM
Br J Cancer; 2013 Apr; 108(6):1288-97. PubMed ID: 23481183
[TBL] [Abstract][Full Text] [Related]
30. CCL2 promotes macrophages-associated chemoresistance via MCPIP1 dual catalytic activities in multiple myeloma.
Xu R; Li Y; Yan H; Zhang E; Huang X; Chen Q; Chen J; Qu J; Liu Y; He J; Yi Q; Cai Z
Cell Death Dis; 2019 Oct; 10(10):781. PubMed ID: 31611552
[TBL] [Abstract][Full Text] [Related]
31. To b(ortezomib) or not to be: the stroma's the thing.
Krem MM; Yan J
J Pathol; 2016 Oct; 240(2):123-5. PubMed ID: 27340009
[TBL] [Abstract][Full Text] [Related]
32. The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages.
Mougiakakos D; Bach C; Böttcher M; Beier F; Röhner L; Stoll A; Rehli M; Gebhard C; Lischer C; Eberhardt M; Vera J; Büttner-Herold M; Bitterer K; Balzer H; Leffler M; Jitschin S; Hundemer M; Awwad MHS; Busch M; Stenger S; Völkl S; Schütz C; Krönke J; Mackensen A; Bruns H
Cancer Immunol Res; 2021 Mar; 9(3):265-278. PubMed ID: 33563611
[TBL] [Abstract][Full Text] [Related]
33. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
[TBL] [Abstract][Full Text] [Related]
34. Onionin A inhibits ovarian cancer progression by suppressing cancer cell proliferation and the protumour function of macrophages.
Tsuboki J; Fujiwara Y; Horlad H; Shiraishi D; Nohara T; Tayama S; Motohara T; Saito Y; Ikeda T; Takaishi K; Tashiro H; Yonemoto Y; Katabuchi H; Takeya M; Komohara Y
Sci Rep; 2016 Jul; 6():29588. PubMed ID: 27404320
[TBL] [Abstract][Full Text] [Related]
35. Antitumor and Antimetastatic Activity of Synthetic Hydroxystilbenes Through Inhibition of Lymphangiogenesis and M2 Macrophage Differentiation of Tumor-associated Macrophages.
Kimura Y; Sumiyoshi M; Baba K
Anticancer Res; 2016 Jan; 36(1):137-48. PubMed ID: 26722037
[TBL] [Abstract][Full Text] [Related]
36. Hypoxia promotes glioma-associated macrophage infiltration via periostin and subsequent M2 polarization by upregulating TGF-beta and M-CSFR.
Guo X; Xue H; Shao Q; Wang J; Guo X; Chen X; Zhang J; Xu S; Li T; Zhang P; Gao X; Qiu W; Liu Q; Li G
Oncotarget; 2016 Dec; 7(49):80521-80542. PubMed ID: 27602954
[TBL] [Abstract][Full Text] [Related]
37. Erythropoietin alleviates hyperglycaemia-associated inflammation by regulating macrophage polarization via the JAK2/STAT3 signalling pathway.
Cui J; Zhang F; Cao W; Wang Y; Liu J; Liu X; Chen T; Li L; Tian J; Yu B
Mol Immunol; 2018 Sep; 101():221-228. PubMed ID: 30007232
[TBL] [Abstract][Full Text] [Related]
38. Alantolactone induces G1 phase arrest and apoptosis of multiple myeloma cells and overcomes bortezomib resistance.
Yao Y; Xia D; Bian Y; Sun Y; Zhu F; Pan B; Niu M; Zhao K; Wu Q; Qiao J; Fu C; Li Z; Xu K
Apoptosis; 2015 Aug; 20(8):1122-33. PubMed ID: 26033479
[TBL] [Abstract][Full Text] [Related]
39. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
Zaman S; Shentu S; Yang J; He J; Orlowski RZ; Stellrecht CM; Gandhi V
Neoplasia; 2015 Mar; 17(3):289-300. PubMed ID: 25810013
[TBL] [Abstract][Full Text] [Related]
40. A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway.
Zhang B; Li B; Xie Y; Chang S; Xu Z; Hu H; Chen G; Zhang T; He J; Wu X; Zhu H; Lai W; Song D; Lu Y; Jia X; Zhu W; Shi J
Acta Biochim Biophys Sin (Shanghai); 2023 Feb; 55(2):215-224. PubMed ID: 36815376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
